Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Parse is focused on providing complete, end-to-end solutions at unprecedented scale. By joining with some of the industry's top automation providers, we are giving customers more extensive choices," said Parse Biosciences co-founder and CEO Alex Rosenberg. "This approach is fundamental to our core belief that single cell RNA sequencing provides valuable insights that should be available to all scientists, whether they're in basic research or in a high-throughput drug development environment."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEATTLE -- Businesswire -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products. By combining powerful automation with the Parse Evercode platform, customers will have unprecedented access to high-throughput single cell sequencing, enabling them to rapidly generate insights for large-scale studies.
Parse’s Evercode single cell technology has enabled researchers to scale their projects to millions of cells or nuclei and has been widely adopted across oncology, immunology, neuroscience, basic research, and drug and target discovery. To facilitate scaling up these projects and to help researchers generate insights more quickly, Parse has developed automation-friendly workflows for high-throughput sample fixation, single cell barcoding, and library preparation.
As key providers in the new Laboratory Automation Provider Program, Hamilton, Opentrons, and SPT Labtech will each collaborate with Parse to automate Parse’s Evercode Whole Transcriptome and Whole Transcriptome Mega workflows on their respective liquid handling platforms. These customized scripts will allow users to purchase application-ready instruments and empower existing users to more easily adapt Parse workflows in their labs.
“Parse is focused on providing complete, end-to-end solutions at unprecedented scale. By joining with some of the industry‘s top automation providers, we are giving customers more extensive choices,” said Parse Biosciences co-founder and CEO Alex Rosenberg. “This approach is fundamental to our core belief that single cell RNA sequencing provides valuable insights that should be available to all scientists, whether they’re in basic research or in a high-throughput drug development environment.”
Hamilton, Opentrons, and SPT Labtech provide versatile liquid handling platforms that support many workflows, in addition to Evercode, providing flexibility and economy to customers who run other protocols in their labs. The companies aim to have automated protocols for the Evercode platform available in coming months.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used by over 1,700 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424893659/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Parse Biosciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 현대자동차, 북미서 수소전기트럭 사업 본격 전개 - 뉴스와이어
- 클린 바디케어 브랜드 데미플로, 첫 전속모델로 배우 ‘이이담’ 발탁 - 뉴스와이어
- 대한항공, 포르투갈 리스본 직항 노선 운항 - 뉴스와이어
- 구조견 ‘줄기세포 치료’로 다리 마비 극복… 반려견 치료 새 장 열리나 - 뉴스와이어
- 팍스젠바이오, 중소벤처기업부 주관 ‘글로벌강소기업 1000+ 프로젝트’ 최종 선정 - 뉴스와이어
- 보쉬 모빌리티 애프터마켓 사업부, 황사와 미세먼지 많은 봄철 내 차에 맞는 에어컨/히터 필터
- TMCA Complex, 메타버스로 모두를 위한 미술관을 꿈꾸다 - 뉴스와이어
- 에덴요양병원, 고속도로 개통으로 접근성 크게 개선 - 뉴스와이어
- 현대자동차그룹, 미국 IIHS 충돌평가 최고 안전한 차 최다 선정 - 뉴스와이어
- 서울그린트러스트, 서울식물원 내 어린이를 위한 열린놀이공간 ‘거인의 정원’ 시즌2 선보여 -